⚠ Evidence warning: Clinical trials or other evidence do not support the claims that pomegranate reverses atherosclerosis and slows prostate cancer. This page keeps it as a report of what people, websites or other media say.

Pomegranate — Benefits Deep Dive

Benefits — scientific infographic poster

Pomegranate (Punica granatum) is described as one of the most antioxidant-dense fruits on Earth. In a 2008 laboratory comparison of bottled drinks sold in the U.S., using four antioxidant tests including oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP), pomegranate juice had the top combined score, at least 20% above red wine, grape, blueberry, black cherry, acai, cranberry, orange and apple juices and iced teas; the authors note that in vitro antioxidant potency does not prove in vivo biological activity. Its bioactivity is not driven by Vitamin C or generic polyphenols but by a specific class of large-molecule ellagitannins — punicalagins — that are unique to pomegranate and largely absent from any other commonly consumed food. These ellagitannins are hydrolyzed in the upper gut and then metabolized by colonic bacteria into urolithins, the circulating compounds researchers credit with most of the cardiovascular, prostate, mitochondrial, and anti-inflammatory effects reported for pomegranate. Much of that mechanism work comes from cells and animals rather than people (see below). Four deep-dive pages below explore the chemistry of the punicalagin-to-urolithin conversion, the prostate cancer prostate-specific antigen-doubling-time evidence (Pantuck UCLA Phase II, and the placebo-controlled trial that followed), the cardiovascular data (the small Aviram carotid IMT study), and the practical question of whether whole arils, juice, or extract delivers the most consistent dose of the active urolithin metabolite.

Deep-Dive Articles

🛡️

Punicalagins & Antioxidants

The pomegranate-specific large-molecule ellagitannins (punicalagins A and B, punicalin, pedunculagin) that are unique to Punica granatum. Hydrolysis to free ellagic acid in the upper gut, conversion by Gordonibacter and Ellagibacter colonic bacteria to urolithins A, B, C, and D, and the urolithin-metabotype concept (UM-A vs UM-B vs UM-0) that explains inter-individual variation in clinical response.

Read the deep dive →
🩺

Prostate & Prostate-Specific Antigen

The Pantuck UCLA Phase II trial, which had no control arm, reported mean prostate-specific antigen (PSA) doubling time rising from 15 to 54 months in men with rising prostate-specific antigen after primary therapy, and its authors called for a placebo-controlled test. In that later placebo-controlled trial (183 men), median doubling time rose in every arm, including placebo (11.1 to 15.6 months), with no significant difference between groups. Mechanism through inhibition of androgen receptor signaling, AKT/mTOR pathway suppression, and direct cytotoxicity to LNCaP, PC-3, and DU-145 prostate cancer cell lines. Practical dosing, the follow-up that did not replicate, and how to interpret the discrepancy.

Read the deep dive →
❤️

Cardiovascular

Aviram's small study of daily pomegranate juice: 10 patients for 1 year, 5 of them continuing to 3 years. Carotid intima-media thickness fell by up to 30% at 1 year, and further juice brought no additional effect on it. Blood pressure reduction (systolic about 5 mmHg and diastolic about 2 mmHg in a meta-analysis of 8 trials), low-density lipoprotein (LDL) oxidation resistance, paraoxonase-1 (PON1) enzyme upregulation, ACE inhibition, and endothelial nitric oxide preservation. Why pomegranate is described as possibly one of the few foods that reverses early atherosclerosis.

Read the deep dive →
🧃

Juice vs Whole

How the arils, the juice, and an extract compare. Differential delivery of punicalagins (Gil 2000 measured 1,500-1,900 mg/L in commercial juice and only traces in juice made from the arils alone, and credits extraction from the fruit rind), ellagic acid (similar across forms), fiber (whole arils only), and sugar load (8 oz juice = 32g sugar = same as cola). How fresh arils for daily eating are weighed against concentrated juice used for limited periods.

Read the deep dive →

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why Pomegranate Is Pharmacologically Distinct From Other Fruits
  3. Research Papers: Punicalagins & Urolithin Metabolism
  4. Research Papers: Prostate Cancer & Prostate-Specific Antigen
  5. Research Papers: Cardiovascular & Atherosclerosis
  6. Research Papers: Forms, Dose, and Bioavailability
  7. Research Papers: Cross-Cutting (Mitochondria, Inflammation, Safety)
  8. External Authoritative Resources
  9. Connections
  10. Featured Videos

Why Pomegranate Is Pharmacologically Distinct From Other Fruits

Most antioxidant-rich foods exert their effects through one of three well-characterized mechanisms: anthocyanins (blueberries, blackberries, red wine), flavanols (green tea, cocoa), or carotenoids (tomatoes, sweet potato, leafy greens). Pomegranate is unusual because it sits in a fourth class largely by itself — the ellagitannins, and specifically a pair of large-molecule ellagitannins called punicalagin A and punicalagin B that are essentially unique to Punica granatum.

  1. Punicalagins are huge molecules — molecular weight roughly 1,084 Da, far too large to be absorbed intact. They are hydrolyzed slowly in the upper gut to release free ellagic acid (302 Da), some of which is absorbed and conjugated by phase-II enzymes in the liver.
  2. The colonic microbiome creates the actual bioactives — the bulk of the unabsorbed ellagitannins and ellagic acid pass to the colon, where specific gut bacteria (genera Gordonibacter and Ellagibacter) sequentially dehydroxylate them to produce urolithins A, B, C, and D. Urolithin A in particular is the principal circulating metabolite and the most extensively studied bioactive.
  3. Urolithin metabotypes explain inter-individual variation — about 10-15% of adults are "urolithin metabotype 0" (UM-0), meaning their microbiome does not make measurable urolithins. These individuals get little or no urolithin from pomegranate intake, though this can change: in one trial, 3 of 6 non-producers (50%) became producers after taking pomegranate extract. The remaining 85-90% split into metabotype A (urolithin A dominant) and metabotype B (urolithin A plus isourolithin A plus urolithin B). Which group responds more is not settled. In a placebo-controlled crossover trial of 49 overweight adults, four capsules a day (640 mg of phenolics) for 3 weeks lowered LDL cholesterol by about 15% and small LDL by about 47%, but only in people with metabotype B, who also had the highest cardiovascular risk at the start.

The therapeutic implication is twofold. First, no other commonly consumed food delivers a meaningful punicalagin dose — not green tea, not red wine, not blueberries. Pomegranate (or walnuts and certain berries at much smaller doses) is the dietary source of the compounds that become urolithins. Second, the microbiome dependence means that pomegranate's effects are not uniform across individuals. The same 8 oz juice that is credited with dramatic cardiovascular and prostate effects in one person may do almost nothing in a UM-0 person with poor gut bacterial diversity. This is also why direct urolithin A supplements have entered the market — they bypass the microbiome conversion step entirely.

The downstream effects credited to urolithin A include mitophagy induction (selective autophagy of damaged mitochondria), androgen receptor inhibition (the proposed basis of the prostate effects), low-density lipoprotein oxidation resistance (the proposed basis of the cardiovascular effects), ACE inhibition (modest blood-pressure lowering), and NF-kB inhibition (broad anti-inflammatory action). All four deep-dive pages below trace these effects back to the punicalagin-to-urolithin conversion as the unifying mechanism.

Much of this comes from laboratory work, not from people. Mitophagy was shown in worms and rodents (Ryu 2016). The androgen findings used pomegranate polyphenols on prostate cancer cells (Hong 2008), the growth findings used pomegranate extracts on prostate cancer cells and in mice (Albrecht 2004), and a urolithin A study used prostate cancer cells at 40 µM for 24 hours (Sánchez-González 2016). The inflammatory-signaling work was done in colon cancer cells (Adams 2006). On LDL oxidation, a small human study points away from a direct effect: in 6 healthy people drinking 1 liter of juice a day for 5 days, the gut-made metabolites did not show significant antioxidant activity compared to punicalagin, and no relevant effect was seen on any blood parameter, although the authors still attribute any whole-body effects to those metabolites (Cerdá 2004).

Human trials in prostate cancer have also tested the fruit directly. In men with advanced prostate cancer, most of them castration-resistant (102 enrolled), 500 ml of pomegranate juice a day for 4 weeks made no difference to PSA or pain scores compared with a placebo drink (Stenner-Liewen 2013).

Back to Table of Contents

Research Papers: Punicalagins & Urolithin Metabolism

  1. Cerdá B et al. (2004). The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr — PubMed PMID: 15309440
  2. Tomas-Barberan FA et al. (2017). Urolithins, the rescue of "old" metabolites to understand a "new" concept: metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res — PubMed PMID: 27158799
  3. Espin JC et al. (2013). Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med — PubMed PMID: 23781257
  4. Selma MV, Tomás-Barberán FA, Beltrán D, et al. (2014). Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int J Syst Evol Microbiol — PubMed PMID: 24744017
  5. Selma MV et al. (2016). The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food Funct — PubMed PMID: 26597167
  6. Seeram NP et al. (2006). Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr — PubMed PMID: 16988113
  7. Gil MI et al. (2000). Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. — PubMed PMID: 11052704
  8. Heber D (2008). Multitargeted therapy of cancer by ellagitannins. Cancer Lett — PubMed PMID: 18468784
  9. Larrosa M et al. (2010). Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem — PubMed PMID: 19616930
  10. Cortes-Martin A et al. (2020). Where to look into the puzzle of polyphenols and health? The postbiotics and gut microbiota associated with human metabotypes. Mol Nutr Food Res — PubMed PMID: 32196920

Back to Table of Contents

Research Papers: Prostate Cancer & Prostate-Specific Antigen

  1. Pantuck AJ et al. (2006). Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clinical Cancer Research — PubMed PMID: 16818701
  2. Pantuck AJ et al. (2015). A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis — PubMed PMID: 26169045
  3. Albrecht M et al. (2004). Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. — PubMed PMID: 15383219
  4. Malik A et al. (2005). Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A — PubMed PMID: 16192356
  5. Hong MY, Seeram NP, Heber D (2008). Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem — PubMed PMID: 18479901
  6. Sanchez-Gonzalez C et al. (2016). Urolithin A causes p21 up-regulation in prostate cancer cells. Eur J Nutr — PubMed PMID: 25962506
  7. Adhami VM et al. (2009). Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer — doi:10.1080/01635580903285064
  8. Paller CJ et al. (2013). A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis — PubMed PMID: 22689129
  9. Stenner-Liewen F et al. (2013). Daily pomegranate intake has no impact on PSA levels in patients with advanced prostate cancer: results of a phase IIb randomized controlled trial. J Cancer — PubMed PMID: 24069070

Back to Table of Contents

Research Papers: Cardiovascular & Atherosclerosis

  1. Aviram M et al. (2004). Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. — PubMed PMID: 15158307
  2. Aviram M et al. (2000). Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr — doi:10.1093/ajcn/71.5.1062
  3. Sahebkar A et al. (2017). Effects of pomegranate juice on blood pressure: a systematic review and meta-analysis of randomized controlled trials. — PubMed PMID: 27888156
  4. Asgary S et al. (2014). Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res — PubMed PMID: 23519910
  5. Sumner MD et al. (2005). Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. — PubMed PMID: 16169367
  6. Aviram M, Dornfeld L (2001). Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis — PubMed PMID: 11500191
  7. Davidson MH et al. (2009). Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol — PubMed PMID: 19766760
  8. Mathew AS et al. (2012). Acute effects of pomegranate extract on postprandial lipaemia, vascular function and blood pressure. Plant Foods Hum Nutr — PubMed PMID: 23093401
  9. Kelishadi R et al. (2011). Acute and long term effects of grape and pomegranate juice consumption on endothelial dysfunction in pediatric metabolic syndrome. J Res Med Sci — PubMed PMID: 22091240
  10. González-Sarrías A et al. (2017). Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: a randomized clinical trial. Mol Nutr Food Res — PubMed PMID: 27879044

Back to Table of Contents

Research Papers: Forms, Dose, and Bioavailability

  1. Seeram NP et al. (2008). Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem — PubMed PMID: 18220345
  2. Mertens-Talcott SU et al. (2006). Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem — doi:10.1021/jf061674h
  3. Gonzalez-Sarrias A et al. (2014). Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. Eur J Nutr — PubMed PMID: 24077694
  4. Andreux PA et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab — doi:10.1038/s42255-019-0073-4
  5. Singh A et al. (2022). Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. Eur J Clin Nutr — PubMed PMID: 34117375
  6. Ryu D et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. — PubMed PMID: 27400265
  7. Heber D et al. (2007). Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. J Agric Food Chem — PubMed PMID: 17966977
  8. Tezcan F et al. (2009). Antioxidant activity and total phenolic, organic acid and sugar content in commercial pomegranate juices. Food Chem — doi:10.1016/j.foodchem.2008.12.103
  9. Stoner GD, Mukhtar H (1995). Polyphenols as cancer chemopreventive agents. J Cell Biochem — doi:10.1002/jcb.240590822

Back to Table of Contents

Research Papers: Cross-Cutting (Mitochondria, Inflammation, Safety)

  1. D'Amico D et al. (2021). Impact of the natural compound urolithin A on health, disease, and aging. Trends Mol Med — doi:10.1016/j.molmed.2021.04.009
  2. Liu S et al. (2022). Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open — PubMed PMID: 35050355
  3. Adams LS et al. (2006). Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem — doi:10.1021/jf052005r
  4. Aviram M et al. (1998). Interactions of paraoxonases with low-density lipoprotein, high-density lipoprotein, and macrophages PubMed search
  5. Rosenblat M et al. (2006). Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis — PubMed PMID: 16226266
  6. Komperda KE (2009). Potential interaction between pomegranate juice and warfarin. Pharmacotherapy — PubMed PMID: 19637955
  7. Hidaka M et al. (2005). Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos — PubMed PMID: 15673597
  8. Forest CP et al. (2007). Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction. — PubMed PMID: 17568759
  9. Trombold JR et al. (2010). Ellagitannin consumption improves strength recovery 2-3 d after eccentric exercise. Med Sci Sports Exerc — PubMed PMID: 19952825
  10. Vidal A et al. (2003). Studies on the toxicity of Punica granatum L. (Punicaceae) whole fruit extracts. J Ethnopharmacol — doi:10.1016/j.jep.2003.09.001

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents